Program June 27

Preliminary Program June 27

08:00-09:00

Industry Session 4: Madrigal Pharmaceuticals Deutschland

09:00-10:00

Industry Session 5: Wörwag Pharma

10:00-11:30

Session 13: DZD Symposium – Innovation in Diabetology

Chairs: Michael Roden (Düsseldorf, Germany), Georgia Xourafa (Düsseldorf, Germany)

Meriem Ouni (Nuthetal, Germany)
Discovery of epigenetic classifiers and predictors of obesity and type 2 diabetes

Michele Solimena (Dresden, Germany)
Coxsackie virus and SARS-CoV2-driven beta cell demise in type 1 diabetes

Andreas Birkenfeld (Tübingen, Germany)
Pathways to prevention of type 2 diabetes

Session 14: Psychosocial aspects and health outcomes research

Chairs: Tomasz Klupa (Krakow, Poland), Tatjana Milenkovic (Skopje, North Macedonia)

Katarzyna Cyranka (Krakow, Poland)
Emotional and cognitive factors shaping health outcomes in chronic disease

Andrea Icks (Düsseldorf, Germany)
Psychosocial outcomes in diabetes subtypes: Results from the German Diabetes Study

Katarina Lalic (Belgrade, Serbia)
A holistic approach to diabetes care: linking psychosocial and clinical factors

Christian Herder (Düsseldorf, Germany)
Inflammation and depression in diabetes

11:30-12:00 – Coffee break

12:00-13:15

Session 15: Obesity

Chairs: José Silva-Nunes (Lisbon, Portugal), Emmanuel Van Obberghen (Nice, France)

Alexandra Chadt (Düsseldorf, Germany)
Obesity in motion: Preclinical insights into genes, signals and lifestyle

Mustafa Cesur (Ankara, Turkey)
A Turkish nationwide study: A real-world comparison of semaglutide and tirzepatide

Nanette Schloot (Bad Homburg, Germany)
New data on retatrutide for treatment of obesity

Session 16: Young Investigator Session 2

Chairs: Nikolaos Papanas (Alexandroupolis, Greece), Kalliopi Pafili (Düsseldorf, Germany)

Theresa Körbel (Vienna, Austria)
Once-weekly semaglutide in type 1 diabetes managed with automated insulin delivery

Roxana Adriana Stoica (Bucharest, Romania)
Modulation of inflammatory pathways by SGLT2 Inhibitors

Martin Schön (Düsseldorf, Germany)
Unraveling diabetes heterogeneity: From mechanisms to clinical application

Michał Kania (Krakow, Poland)
Oral microbiota in people with diabetes – does it matter?

Stella Papachristou (London, UK; Alexandroupolis, Greece)
AGEs and diabetic neuropathy